Uncategorized
Vitreomacular interface affects anti-VEGF injection intervals for AMD
PHILADELPHIA — The presence of vitreomacular interface appears to significantly affect anti-VEGF injection intervals for treatment of age-related macular degeneration, according to a study presented here. Patients with or without vitreomacular adhesion (VMA) showed similar outcomes, with VMA patients requiring more intensive treatment with a diminished ability to lengthen intervals between injections, Samuel K. Houston III, MD, said at the Wills Eye Annual Conference. “The anatomic factors may contribute to individual treatment responses and should be evaluated and considered in treatment decisions for neovascular AMD,” Houston said.